---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-237227"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:41:29.605793+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Benitec reports positive interim data from BB-301 Phase 1b/2a: swallowing improvements in two OPMD subjects

## Summary
- Subject 1 at Day 270: 35% SSQ Total Score reduction, 33% VFSS TPR reduction for thin liquids.
- Subject 2 at Day 180: 89% SSQ Total Score reduction (score 82, clinically normal swallowing), 92% reduction in low-volume sequential swallows.
- No Significant Adverse Events observed with low-dose BB-301 (1.2e13 vg/subject).
- Third subject to be dosed this month; higher-dose cohorts enrollment expected in 2025.

## SEC filing metadata
- accession: 0001193125-24-237227
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312524237227/0001193125-24-237227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312524237227/d863953d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-237227
- JSON: https://secwatch.observer/filing/0001193125-24-237227.json
- Plain text: https://secwatch.observer/filing/0001193125-24-237227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.